Nataliya Pyslar, MD
Cardiovascular Disease · Park Ridge, ILNPI 1033352703
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $3,252 of the $5,166 with a category attached, or 63.0%. Regeneron accounts for 65.2% of it on its own, with 8 other manufacturers making up the rest. 2025 is the largest year on record at $3,718, more than ten times the $366 reported in 2019.
Across 29 payments — averaging $178.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron$3K
- Amgen$972
- Regeneron Healthcare Solutions, Inc.$251
- Medicure Pharma Inc.$153
- Esperion Therapeutics, Inc.$149
- Sanofi-aventis U.S. LLC$115
- plus $160 from 3 others
Across 7 payments — averaging $8164.58 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$54K
- Regeneron$3K
- Novartis$213
What the payments were for
- Consulting fees$3,25263%
- Food & beverage$1,91437%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron | 3 | $3,366 |
| Amgen | 9 | $972 |
| Regeneron Healthcare Solutions, Inc. | 4 | $251 |
| Medicure Pharma Inc. | 1 | $153 |
| Esperion Therapeutics, Inc. | 4 | $149 |
| Sanofi-aventis U.S. LLC | 1 | $115 |
| Abbott | 4 | $80 |
| Novartis | 2 | $53 |
| Boston Scientific | 1 | $26 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EVKEEZA$3,366
- Repatha$668
- ZYPITAMAG (pitavastatin)$153
- NO PRODUCT DISCUSSED$115
How this compares
$5,166 in reported general payments places this provider in the 70th percentile of 932 cardiovascular disease providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Repatha SureclickEvolocumab | 49 | $29,473 |
| Praluent PenAlirocumab | 22 | $14,960 |
| Ezetimibe | 61 | $1,681 |
| Metoprolol Succinate | 47 | $1,018 |
| Rosuvastatin Calcium | 36 | $895 |
| Nifedipine ErNifedipine | 14 | $400 |
| Atorvastatin Calcium | 35 | $287 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 24 | $127 |
| Furosemide | 22 | $115 |
| Spironolactone | 12 | $68 |
| Carvedilol | 14 | $58 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Park Ridge
- Sandeep NathanChicago$892K
- Alan BrownNaperville$858K
- Azmey MatariehElgin$762K
- Jay AlexanderBannockburn$744K
- Niraj VarmaMaywood$522K
- Boaz AvitallChicago$366K
- Akhil NarangChicago$363K
- Mark RabbatMaywood$363K
- Michael DavidsonChicago$317K
- Robert KochLibertyville$298K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.